Renal protection of in vivo administration of tempol in streptozotocin-induced diabetic rats

Jiajie Luan, Weiping Li, Jia Han, Wen Zhang, Huiling Gong, Rong Ma

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

Abstract

The present study was carried out to investigate the protective effects of tempol on renal function and the underlying mechanism in streptozotocin-induced diabetic rats. The diabetic rats were randomly divided into the model group (without tempol) and tempol group (1 mM tempol in drinking water for 6 weeks). Nondiabetic rats were served as the Control group. The mRNA expression of canonical transient receptor potential 6 (TRPC6), transforming growth factor (TGF)-β1, and type IV collagen (Col IV) were examined. The malondialdehyde (MDA) level, activities of superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) in renal tissues were measured to assess redox status in kidneys. We found that tempol significantly reduced 24-h urine output and urine albuminuria excretion in the diabetic rats. Compared with the model group, the concentration of MDA was significantly lower in the tempol group. In addition, diabetes decreased activities of SOD and GSH-Px and these responses were prevented by tempol treatment. Moreover, in diabetic rats, the mRNA expression levels of TGF-β1 and Col IV were upregulated. TRPC6 mRNA expression level was down-regulated in diabetic kidneys. However, all of these diabetic effects were significantly suppressed by tempol treatment. These results suggest that chronic treatment of diabetic rats with tempol can protect kidneys, possibly by reducing expression of TGF-β1, Col IV, and upregulating TRPC6 expression level.

Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalJournal of Pharmacological Sciences
Volume119
Issue number2
DOIs
StatePublished - 4 Jul 2012

Fingerprint

Streptozocin
Kidney
Transforming Growth Factors
Malondialdehyde
Messenger RNA
Superoxide Dismutase
Urine
tempol
Albuminuria
Glutathione Peroxidase
Collagen Type I
Drinking Water
Oxidation-Reduction
Control Groups

Keywords

  • Collagen IV
  • Diabetic nephropathy
  • Tempol
  • Transforming growth factor-β
  • Transient receptor potential 6 (TRPC6)

Cite this

Luan, Jiajie ; Li, Weiping ; Han, Jia ; Zhang, Wen ; Gong, Huiling ; Ma, Rong. / Renal protection of in vivo administration of tempol in streptozotocin-induced diabetic rats. In: Journal of Pharmacological Sciences. 2012 ; Vol. 119, No. 2. pp. 167-176.
@article{28e45a26630740f9a5fe1d074bfd96d5,
title = "Renal protection of in vivo administration of tempol in streptozotocin-induced diabetic rats",
abstract = "The present study was carried out to investigate the protective effects of tempol on renal function and the underlying mechanism in streptozotocin-induced diabetic rats. The diabetic rats were randomly divided into the model group (without tempol) and tempol group (1 mM tempol in drinking water for 6 weeks). Nondiabetic rats were served as the Control group. The mRNA expression of canonical transient receptor potential 6 (TRPC6), transforming growth factor (TGF)-β1, and type IV collagen (Col IV) were examined. The malondialdehyde (MDA) level, activities of superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) in renal tissues were measured to assess redox status in kidneys. We found that tempol significantly reduced 24-h urine output and urine albuminuria excretion in the diabetic rats. Compared with the model group, the concentration of MDA was significantly lower in the tempol group. In addition, diabetes decreased activities of SOD and GSH-Px and these responses were prevented by tempol treatment. Moreover, in diabetic rats, the mRNA expression levels of TGF-β1 and Col IV were upregulated. TRPC6 mRNA expression level was down-regulated in diabetic kidneys. However, all of these diabetic effects were significantly suppressed by tempol treatment. These results suggest that chronic treatment of diabetic rats with tempol can protect kidneys, possibly by reducing expression of TGF-β1, Col IV, and upregulating TRPC6 expression level.",
keywords = "Collagen IV, Diabetic nephropathy, Tempol, Transforming growth factor-β, Transient receptor potential 6 (TRPC6)",
author = "Jiajie Luan and Weiping Li and Jia Han and Wen Zhang and Huiling Gong and Rong Ma",
year = "2012",
month = "7",
day = "4",
doi = "10.1254/jphs.12002FP",
language = "English",
volume = "119",
pages = "167--176",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8613",
publisher = "Japanese Pharmacological Society",
number = "2",

}

Renal protection of in vivo administration of tempol in streptozotocin-induced diabetic rats. / Luan, Jiajie; Li, Weiping; Han, Jia; Zhang, Wen; Gong, Huiling; Ma, Rong.

In: Journal of Pharmacological Sciences, Vol. 119, No. 2, 04.07.2012, p. 167-176.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Renal protection of in vivo administration of tempol in streptozotocin-induced diabetic rats

AU - Luan, Jiajie

AU - Li, Weiping

AU - Han, Jia

AU - Zhang, Wen

AU - Gong, Huiling

AU - Ma, Rong

PY - 2012/7/4

Y1 - 2012/7/4

N2 - The present study was carried out to investigate the protective effects of tempol on renal function and the underlying mechanism in streptozotocin-induced diabetic rats. The diabetic rats were randomly divided into the model group (without tempol) and tempol group (1 mM tempol in drinking water for 6 weeks). Nondiabetic rats were served as the Control group. The mRNA expression of canonical transient receptor potential 6 (TRPC6), transforming growth factor (TGF)-β1, and type IV collagen (Col IV) were examined. The malondialdehyde (MDA) level, activities of superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) in renal tissues were measured to assess redox status in kidneys. We found that tempol significantly reduced 24-h urine output and urine albuminuria excretion in the diabetic rats. Compared with the model group, the concentration of MDA was significantly lower in the tempol group. In addition, diabetes decreased activities of SOD and GSH-Px and these responses were prevented by tempol treatment. Moreover, in diabetic rats, the mRNA expression levels of TGF-β1 and Col IV were upregulated. TRPC6 mRNA expression level was down-regulated in diabetic kidneys. However, all of these diabetic effects were significantly suppressed by tempol treatment. These results suggest that chronic treatment of diabetic rats with tempol can protect kidneys, possibly by reducing expression of TGF-β1, Col IV, and upregulating TRPC6 expression level.

AB - The present study was carried out to investigate the protective effects of tempol on renal function and the underlying mechanism in streptozotocin-induced diabetic rats. The diabetic rats were randomly divided into the model group (without tempol) and tempol group (1 mM tempol in drinking water for 6 weeks). Nondiabetic rats were served as the Control group. The mRNA expression of canonical transient receptor potential 6 (TRPC6), transforming growth factor (TGF)-β1, and type IV collagen (Col IV) were examined. The malondialdehyde (MDA) level, activities of superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) in renal tissues were measured to assess redox status in kidneys. We found that tempol significantly reduced 24-h urine output and urine albuminuria excretion in the diabetic rats. Compared with the model group, the concentration of MDA was significantly lower in the tempol group. In addition, diabetes decreased activities of SOD and GSH-Px and these responses were prevented by tempol treatment. Moreover, in diabetic rats, the mRNA expression levels of TGF-β1 and Col IV were upregulated. TRPC6 mRNA expression level was down-regulated in diabetic kidneys. However, all of these diabetic effects were significantly suppressed by tempol treatment. These results suggest that chronic treatment of diabetic rats with tempol can protect kidneys, possibly by reducing expression of TGF-β1, Col IV, and upregulating TRPC6 expression level.

KW - Collagen IV

KW - Diabetic nephropathy

KW - Tempol

KW - Transforming growth factor-β

KW - Transient receptor potential 6 (TRPC6)

UR - http://www.scopus.com/inward/record.url?scp=84863083735&partnerID=8YFLogxK

U2 - 10.1254/jphs.12002FP

DO - 10.1254/jphs.12002FP

M3 - Article

VL - 119

SP - 167

EP - 176

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8613

IS - 2

ER -